Canaccord Genuity Doubles Price Target for Medivation
Medivation received an upgrade from Canaccord Genuity, citing the company’s potential drug sales of Xtandi as undervalued.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Medivation Inc. (NASDAQ: MDVN) received an upgrade from Canaccord Genuity on the heels of it continually increasing its 52-week high over the past month. This upgrade comes on analyst John Newman’s estimate that the company’s potential drug sales of Xtandi are undervalued.
The company developed Xtandi for the treatment of metastatic castration-resistant prostate cancer, and it received FDA approval in 2012.
Newman states that, although there is no formal head-to-head trial, Xtandi matches up well against its rival Zytiga, produced by Cadila Pharmaceuticals. Xtandi provides a greater reduction in death, 29% compared to Zytiga’s 21%. Also a reduced risk of radiographic progress or death, by 83% versus 57%. He concludes that Xtandi is a better product and will look to take up more market share as time goes on.
Newman predicts that that potential revenue from Xtandi will be around $4.5 billion in the pre-chemo setting by 2023. The U.S. peak sales alone are estimated at $2.7 billion in the pre-chemo setting.
Medivation has surpassed its highs from February of $88.20 and gradually continues to move up the chart. Thursday it posted its most recent high of $100.48.
Canaccord Genuity upgraded its rating on Medivation to Buy from Hold, as well as more than doubling its price target to $132.00 from the previous target of $60.00.
ALSO READ: Analyst Sees Incyte Worth 70% More
The earnings per share estimate for 2014 has been revised to $1.88 from $3.03. The estimate for 2015 has been revised to $0.39 from $1.93 per share.
Annual revenue for 2014 was revised to $632.8 million from $516.3. Revenues for 2015 were revised to $652.0 million from $594.5.
Medivation has a consensus price target of $102.00, and it has a 52-week trading range of $48.15 to $100.48. The market cap for this company is $7.67 billion.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
